© Copyright Acquisition International 2024 - All Rights Reserved.

Article Image - Building a Better Future
Posted 30th April 2020

Building a Better Future

There are few things in the world that can unite people quite like the universal burden of cancer and neurodegenerative diseases. A company located on the German border near the Czech Republic remains wholly dedicated to the ongoing fight to erase these diseases forever. After its recognition as a Leading Innovator in AI-Based Personalised Medicine Solutions 2020 – Germany, we shine a light on the work of BioVariance GmbH in this latest issue of Acquisition International.

Mouse Scroll AnimationScroll to keep reading

Let us help promote your business to a wider following.

Building a Better Future
BioVariance GmbH

There are few things in the world that can unite people quite like the universal burden of cancer and neurodegenerative diseases. A company located on the German border near the Czech Republic remains wholly dedicated to the ongoing fight to erase these diseases forever. After its recognition as a Leading Innovator in AI-Based Personalised Medicine Solutions 2020 – Germany, we shine a light on the work of BioVariance GmbH in this latest issue of Acquisition International.

When someone becomes sick, physicians usually draw on the common range of medicines and pills. Paracetamol, Ibuprofen and other household drug brands will help most people overcome a headache or other minor aches. However, for the severe cases, such as cancer or neurodegenerative diseases, there is a rapid and strong need to find the right type of medicine that patients will potentially respond to. It is this need that the team of BioVariance have sought to address, by analysing complex biomedical and genetic data from patients to ensure they receive a personalized treatment. Founded in 2013 and headquartered in Waldsassen, Germany, BioVariance’s multidisciplinary team consisting of software developers, biologists and data scientists develops innovative AI solutions for precision medicine in the healthcare, biotech and pharmaceutical sectors.

In cooperation with oncological clinics, laboratories, pharmaceutical companies and physicians all over the country, BioVariance offers long-term monitoring of molecular changes in patients to predict the effectiveness, side effects and drug interactions of specific medications. The company also helps to determine the optimal medication and dosage for each patient individually. Achieving this level of information is not easy at all and requires the combination of profound knowledge with state-of-the-art automatization and parallelization techniques, machine learning and mathematical algorithms to analyse complex biomedical data.

The vision of BioVariance is shared by people all over the world: the eradication of complex diseases and the increase of survival rates by making cancer and neurodegenerative diseases as treatable as the common cold. The company totally focuses on the improvement of patient’s health and quality of life by analysing and interpreting his biomedical data. Working at the junction of some of the most modern technologies, BioVariance represents the fusion of molecular genetics, big data and artificial intelligence that enables personalized care as never before.

For the multidisciplinary team this work is more than just a job. The work culture is characterised by technological advancement, insatiable curiosity and open-mindedness, based on five core values: integrity, responsibility, collaboration, professionalism and innovation. Rather than seeking to maximise profits, BioVariance values patient care above everything else and strives every day to save human lives.

BioVariance offers its services to pharmaceutical companies, physicians and patients themselves. Pharma companies are supported in the analysis of complex molecular biological and biomedical data by using state-of-the-art techniques to identify fundamental correlations across all biological levels, from DNA to metabolites. The application of machine learning, neuronal networks, mathematical algorithms and statistical methods in combination with existing clinical data ensure the high quality of the analytical results.

All results are validated by searching comprehensive medical literature, with the patient’s data being compared with data already existing in the fields of biology, pharmacology and medicine. By understanding, identifying and evaluating biological markers and molecular signatures, pharma companies can be prepared more than ever to develop new effective drugs and personalized treatments.

These personalized applications are then transferred to the other two focus areas of BioVariance: the physician and the patient. For physicians, the company aims to provide more efficient options when a personalized treatment is required. The goal of personalized medicine is to determine the most suitable medication in the optimal dosage for each patient individually. This is rarely easy, however. Doctors and physicians all over the world depend on correct medical diagnoses that consider the personal characteristics and circumstances of a patient’s life, as well as their genetic and molecular biological background. Comprehensive and accurate genetic analyses can ensure that physicians prescribe only the most effective treatment and avoid wrong prescriptions which lead to strong side effects in the worst case. This is where BioVariance comes in.

Analysing individual genetic characteristics and then comparing them with global literature can help physicians and hospitals optimize therapy and adapt it to the specific needs of the patient. Attending physicians and hospitals all over the country and worldwide can access comprehensive reports that contain information about the patient’s diagnosis, current therapies, previous medications and the results of BioVariance’s genetic analysis. Additionally, information about possible side effects and drug interactions that may occur during certain therapies support the selection of an effective treatment.

Considering genetic impacts, physicians and hospitals can avoid non-responsive therapies, eliminate potential side effects, raise survival rates, increase patients’ satisfaction and save valuable time in the treatment process. The genetic fingerprint of an individual helps determine how it may react to a certain treatment or medication. By tailoring therapies, BioVariance helps alleviate patients’ concerns by ensuring their therapy is designed specifically for them.

A challenge of any therapy is the independent intake of medication; another factor the team of BioVariance has carefully dealt with. The company’s mobile app Pillbox reminds patients to take their medication at a specific time and in the correct dosage. Further, the app documents the therapeutic process, symptoms and side effects to inform the attending physician whether an exchange of medication or an adjustment of dosage is necessary. Being a technical marvel, Pillbox also comes with a diary function, an integrated barcode scanner for an easy addition of drugs to the treatment plan and a chat function allowing direct communication between patient and physician.

Cancer and neurodegenerative diseases are undoubtedly some of the greatest medical concerns of our time, but some that the community is actively working towards addressing every single day. For today’s diagnosed patients the wonders of modern medicine and technology represent more than just a chance. It represents hope. Hope for a brighter future, where families are no longer torn apart by death and disease. Hope that, one day, these diseases will be nothing more than a distant memory.

Contact Details:
Company: BioVariance GmbH
Contact: Dr Josef Scheiber
Website: www.biovariance.com

Categories: Innovation, Leadership


You Might Also Like
Read Full PostRead - Eye Icon
BTCGaw is Now Buying Bitcoins With 11% More Than Blockchain Official Rate
Finance
09/04/2015BTCGaw is Now Buying Bitcoins With 11% More Than Blockchain Official Rate

BTCGaw INC. has announced yesterday its latest offer for Bitcoin sellers: a conversion rate with an 11% increase compared to Blockchain's official rate.

Read Full PostRead - Eye Icon
Roland Jonkhoff Appointed Managing Director of Desso
Finance
02/04/2015Roland Jonkhoff Appointed Managing Director of Desso

Desso, a leading carpets and sport pitches company (part of Tarkett), today announced the appointment of Roland Jonkhoff (46) as Managing Director of Desso.

Read Full PostRead - Eye Icon
Financing a Sustainable Future: High-Level Working Group On Green & Sustainability Sukuk Releases Its First Report
Corporate Social Responsibility
26/10/2022Financing a Sustainable Future: High-Level Working Group On Green & Sustainability Sukuk Releases Its First Report

Global green and sustainability sukuk issuance totalled $4.4 billion during the first half of 2022, following a record annual issuance of $6.1 billion in 2021, according to data published by the High-Level Working Group (HLWG) on Green and Sustainability Sukuk

Read Full PostRead - Eye Icon
Placing Ethical and Human Values at the Heart of all Relationships
Legal
30/08/2019Placing Ethical and Human Values at the Heart of all Relationships

UrbanLaw Avocats provides legal advice and assistance to public entities (national or local), as well as major French and international groups. Following their success in AI’s Global Excellence Awards 2019 where they were selected as the Best Urban Planning

Read Full PostRead - Eye Icon
Sweet Success: Katjes International Acquisition of Piasten
Strategy
19/01/2015Sweet Success: Katjes International Acquisition of Piasten

In September 2014, German confectionary company Katjes International acquired Piasten, the largest German producer of sugar-coated products. Tobias Bachmüller, Managing Shareholder of Katjes International, told us more about Katjes International’s continuin

Read Full PostRead - Eye Icon
Should I Switch to a New Payroll Provider Mid-Year?
Finance
30/09/2021Should I Switch to a New Payroll Provider Mid-Year?

Business owners (regardless of size) are not fond of change. That’s because change usually comes in the same package with new investments and disruption of activity. However, when it’s needed for the improvement of your business process and a better future

Read Full PostRead - Eye Icon
The Wallet of the Future
Finance
30/11/2016The Wallet of the Future

Allied Wallet is a world leader in payment processing and merchant services, enabling consumers to transact with merchants at a very low rate.

Read Full PostRead - Eye Icon
The Top Trends in Company Formations
Leadership
22/12/2016The Top Trends in Company Formations

Hawksford Roundtable

Read Full PostRead - Eye Icon
Solteq Acquires inPulse Works Oy
M&A
12/06/2017Solteq Acquires inPulse Works Oy

Solteq Plc has acquired inPulse Works Oy. The acquisition will enable Solteq to offer services that meet the varying needs of electricity, district heating and water companies.



Our Trusted Brands

Acquisition International is a flagship brand of AI Global Media. AI Global Media is a B2B enterprise and are committed to creating engaging content allowing businesses to market their services to a larger global audience. We have 14 unique brands, each of which serves a specific industry or region. Each brand covers the latest news in its sector and publishes a digital magazine and newsletter which is read by a global audience.

Arrow